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INTRODUCTION
A Phosphate Centric Forum, supported by Gen-
zyme Corporation, was held on 24–25 June, 2010 at 
the Sheraton West Park Hotel, Munich, Germany, 
in which 25 medical and scientifi  c experts in the 
fi  eld of chronic kidney disease-related mineral and 
bone disorder (CKD-MBD) met to present and 
discuss the central role of phosphate in the devel-
opment of CKD-MBD, on which research has now 
celebrated its 50th anniversary.
Phosphate plays a central role in the patho-
physiology of CKD-MBD and the progression 
of CKD and contributes to the disproportion-
ate cardiovascular risk faced by patients with 
CKD. Adaptation of nephrons attempting 
to preserve phosphate homeostasis requires 
endocrine tradeoff  s that fuel adverse events 
of hyperphosphatemia in CKD—secondary 
hyperparathyroidism, calcium and vitamin 
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D derangements, vascular calcifi  cation, and 
metabolic bone disorder. Restricting phosphate 
absorption by use of phosphate binders as 
glomerular fi  ltration rate declines reduces the 
need for nephron adaptation and therefore 
forestalls physiologic derangements down-
stream of hyper  phosphatemia.
A roundtable discussion included the patho-
physiology of CKD-MBD, discoveries such as 
the vitamin D receptor, calcium-sensing recep-
tor, fibroblast growth factor (FGF)-23, and 
currently available treatment options, as well 
as future needs regarding research and manage-
ment of this disorder.
Discussants concluded that placebo-
  controlled trials are needed in CKD stages 
2–4 to investigate the eff  ect of phosphate and 
phosphate binders on mortality. Various other 
endpoints were suggested, such as bone disease, 
progression of CKD, and cardiovascular events. 
Ongoing studies investigating a broad range of 
cardiovascular surrogates are due for comple-
tion in 2011. Monitoring methods using the 
less expensive option of phosphate and creati-
nine are preferred over FGF-23 at the present 
time, and studies investigating patients over 
50–55 years of age with high levels of FGF-23 
have been suggested to provide the most valu-
able data. However, it was generally agreed that 
FGF-23 may be a uremic toxin, which would 
support development of anti-FGF-23 strategies 
in the future.
Development of other therapeutic targets, 
including biomarkers that assess function 
of NaPi2a, b, or c (to decrease the reabsorp-
tion of phosphate) or Klotho, is consid-
ered to be challenging but should remain a 
long-term goal. The effects of infusion of sol-
uble Klotho, how the bone senses phosphate, 
and why high levels of FGF-23 are found in 
non-renal organs are other areas of interest 
for future research.
Th   is supplement provides a review of fi  ve 
of the topics discussed during the forum: Dr 
Slatopolsky presents the history of the intact 
nephron hypothesis and its current implica-
tions; Dr Confavreux presents a very new facet 
of the bone, from a reservoir of minerals to a 
regulator of energy metabolism; Dr Hruska 
develops the cardiovascular risk factors in 
CKD; and Dr Jüppner and Dr Kuro-o revisit 
the classic physiology in light of the recent dis-
coveries of FGF-23 and Klotho.
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